Most Read Articles
6 days ago
Living a sedentary lifestyle may increase the risk of cardiovascular diseases (CVD) even in people with healthy body mass index (BMI), reports a new study.
04 Feb 2019
The carbon-chain length of saturated fatty acids appears to be an important factor in determining its role in cardiovascular health, a recent study has found.
4 days ago
Olanzapine confers a modest therapeutic effect on weight compared with placebo in adult outpatients with anorexia nervosa, a study has shown. However, it does not appear to offer significant benefit for psychological symptoms.
Jairia Dela Cruz, 04 Feb 2019
Treatment with secukinumab results in a higher rate of remission or low-disease activity at week 16 in patients with psoriatic arthritis as compared with placebo, according to a posthoc analysis of the FUTURE 2 study. This effect is sustained at 2 years and is evident in both tumour necrosis factor inhibitor-experienced and -naïve patients.

Product Highlight-Skycellflu

27 Sep 2018
SKYCELLFLU – Inactivated quadrivalent influenza vaccine (inj) 0.5 mL - AJ Biologics

The World’s First Cell Culture-Derived Inactivated Influenza Vaccine1


• Optimized immunogenicity with >95% seroprotection rates against all strains in adults and >90% in children ≥3 years2-3
• Tolerable safety profiles in adults and children ≥3 years2-3
• Contains no eggs, no preservatives and no antibiotics1

References:
1. Korea Ministry of Food and Drug Safety. [http://www.mfds.go.kr/eng/brd/m_30/view.do?seq=70648]. Accessed July 24, 2018.
2. Choi WS, Noh JY, Song JY, et al. Immunogenicity and safety of a cell culture-derived inactivated quadrivalent influenza vaccine (NBP607-QIV): A randomized, double-blind, multi-center, phase III clinical trial in adults and elderly subjects. Hum Vaccin Immunother 2017; 13(7): 1653-1660.
3. Kim YK, Eun BW, Lee TJ, et al. Immunogenicity and Safety of a Cell Culture-Derived Inactivated Quadrivalent Influenza Vaccine (NBP607-QIV) in South Korean Children and Adolescents: A Randomized, Double-Blind, Multi-Center, Phase 3 Clinical Trial. Open Forum Infect Dis 2016; Vol 3(Suppl 1): 763.

Further information is available in section 12b, New In This Issue and mims.com
Full prescribing information is available upon request.                                                                                                                                                                                                                                                                                                MY-SCF-000001-08/18

Related MIMS Drugs

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Doctor - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
6 days ago
Living a sedentary lifestyle may increase the risk of cardiovascular diseases (CVD) even in people with healthy body mass index (BMI), reports a new study.
04 Feb 2019
The carbon-chain length of saturated fatty acids appears to be an important factor in determining its role in cardiovascular health, a recent study has found.
4 days ago
Olanzapine confers a modest therapeutic effect on weight compared with placebo in adult outpatients with anorexia nervosa, a study has shown. However, it does not appear to offer significant benefit for psychological symptoms.
Jairia Dela Cruz, 04 Feb 2019
Treatment with secukinumab results in a higher rate of remission or low-disease activity at week 16 in patients with psoriatic arthritis as compared with placebo, according to a posthoc analysis of the FUTURE 2 study. This effect is sustained at 2 years and is evident in both tumour necrosis factor inhibitor-experienced and -naïve patients.